New research suggests that patients who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who end traditional diet and exercise regimens.
Research printed in a major health publication demonstrates that while overweight individuals often shed about a fifth of their total mass while using the jabs, the weight comes back at an average rate of 0.8 kg per month after stopping.
"Individuals purchasing these drugs must be cognizant of the risk of quick rebound weight gain when the therapy ends," warns lead investigator Dr. Susan Jebb.
That rate of recovery implies a reversion to starting mass in about a year and a half.
Weighing Approaches
The analysis, which looked at dozens of trials involving thousands of participants, contrasted the effects of GLP-1 agonists with other pills.
The team point out that individuals who shed pounds through lifestyle changes alone generally see a less rapid creep back—perhaps 100 grams monthly—after stopping.
Understanding the Quick Rebound
Experts propose the mechanism of the jabs explains the heightened weight return.
GLP-1 drugs imitate a natural hormone called GLP-1, which moderates hunger.
"Long-term administration of the hormone concentrations several times higher than the body's typical production may cause the system to produce less of its own natural GLP-1, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' means appetite is uncontrolled, making excessive eating a significant risk."
An Ongoing Issue?
Health authorities recommend the jabs for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
Many experts say that, considering the likelihood of relapse, the therapy might need to be ongoing.
This opinion is supported by pharmaceutical companies, who state that the results "underscore the chronic character of obesity," similar to managing diseases like hypertension.
Patient Accounts
Users who have discontinued the jabs describe a sudden return of appetite.
"It felt as if a trigger activating and I was suddenly starving," described a patient.
The struggle is exacerbated if users have not established lasting lifestyle or habit modifications during therapy.
Significant Use
Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Use is higher among females than men.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion access the medications through private healthcare rather than public health services.
Ultimately, researchers caution that while these medications are potent agents for shedding pounds, they are not a magic fix and lasting health benefits relies on combined behavioural management.
